Vanguard Group Inc. Sells 8,287 Shares of United Therapeutics Corporation $UTHR

Vanguard Group Inc. lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 0.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,448,848 shares of the biotechnology company’s stock after selling 8,287 shares during the quarter. Vanguard Group Inc. owned about 9.86% of United Therapeutics worth $1,278,376,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. AE Wealth Management LLC acquired a new stake in United Therapeutics in the 1st quarter worth $248,000. Avantax Advisory Services Inc. lifted its stake in shares of United Therapeutics by 226.5% in the first quarter. Avantax Advisory Services Inc. now owns 1,933 shares of the biotechnology company’s stock valued at $596,000 after buying an additional 1,341 shares during the period. Skandinaviska Enskilda Banken AB publ grew its position in United Therapeutics by 20.1% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 100,854 shares of the biotechnology company’s stock worth $31,090,000 after buying an additional 16,849 shares in the last quarter. Mediolanum International Funds Ltd grew its position in United Therapeutics by 192.2% during the first quarter. Mediolanum International Funds Ltd now owns 15,257 shares of the biotechnology company’s stock worth $4,683,000 after buying an additional 10,036 shares in the last quarter. Finally, Applied Finance Capital Management LLC increased its stake in United Therapeutics by 3.7% during the first quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 40 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $400.56, for a total transaction of $9,012,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 519,935 shares of company stock valued at $224,879,377 in the last quarter. 10.30% of the stock is owned by insiders.

United Therapeutics Price Performance

Shares of UTHR stock opened at $474.82 on Friday. The stock’s fifty day simple moving average is $439.78 and its 200 day simple moving average is $355.90. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $485.32. The firm has a market cap of $20.44 billion, a price-to-earnings ratio of 17.99, a P/E/G ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period last year, the business earned $6.39 earnings per share. The business’s revenue was up 6.8% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on UTHR shares. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Royal Bank Of Canada upped their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. UBS Group boosted their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.